Search
for
Sort by
Research
300-330 / 1000+ results
research Steroid 5α-Reductase Inhibitors
New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
research Finasteride reduces serum PSA to a similar extent at 1 mg and 5 mg daily doses
Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
research Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study
Finasteride didn't significantly improve ICPPS symptoms, more research needed.
research Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation
Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
research UP-03.25
Finasteride may help treat BPH by affecting certain biological markers.
research Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss☆, ☆☆, ★, ★★
research Effects of PNU157706, a Dual 5α-Reductase Inhibitor, on Rat Epididymal Sperm Maturation and Fertility1
PNU157706 reduced rat sperm movement and fertility without affecting offspring health.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Finasteride for prostatic disease: an updated and comprehensive review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research 5α‐reductase inhibitors: Evaluation of their potential confounding effect on GC‐C‐IRMS doping analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.
research Medications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries
Certain medications, especially Paroxetine, Tamsulosin, and Finasteride, are linked to ejaculatory disorders.
research Effects of 5-alpha reductase inhibitors
5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
research Intracavernous injection of platelet‐rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging‐induced erectile dysfunction rat model
Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.
research Editorial Comment
More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research Finasterida: Diez Años De Uso Clínico. Revisión Sistemática De La Literatura
Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
research Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
research 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
research 5α‐Reductase Isozymes and Androgen Actions in the Prostate
5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research MP85-03 SEXUAL DYSFUNCTION IN MEN WITH PRE-DIABETES – RESULTS FROM A CROSS-SECTIONAL STUDY
Men with prediabetes have worse sexual health and a higher risk of severe erectile dysfunction.
research Drug–Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance
Combining tadalafil and finasteride improves their solubility and effectiveness.
research Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study
Taking medication for hair loss might cause sexual problems.
research Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride
Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.